Chain Drug Review, April 29, 2019

State of the Industry The Issues Policy FDA poised to its hold first public CBD hearing WASHINGTON The Food recognizes the potential as a dietary supplement Prior to to the agency to soften that and Drug Administration is set opportunities that cannabis or stepping down as FDA commissioner stance The Consumer Healthcare to hold its first public hearing cannabis derived compounds earlier this month Scott Products Association on May 31 about products that could offer and insisted that Gott lieb reiterated that in order CHPA recently called on the contain cannabis compounds the FDA is pursuing a regulatory to be classified as a dietary supplement FDA to establish clear regulatory such as CBD The hearing is framework that would allow a substance cannot pathways for CBD as a new meant to gather information as product developers to lawfully have also been authorized as a dietary ingredient the FDA considers regulating market CBD products drug or medicine as CBD was CHPA said it supports a new such products and the agency As the regulatory process when the FDA OKd Epidiolex drug path for cannabis derived said no decisions are imminent plays out a key question is as an epilepsy treatment products that make disease related Meanwhile state and city whether CBD will be classified CBD advocates are appealing claims either prescription lawmakers are making their own rules on the sale of food beverages lotions bath bombs and pet snacks made with CBD as well as the marketing claims about the products benefits As regulators gather evidence or over the counter that are supported by appropriate evidence with FDA approved labeling Its our belief that FDA and stakeholders should work together to further develop pathways for hemp and CBD containing products both medicines and dietary supplements to safely reach consumers CHPA said in a statement Leading the way to a healthier tomorrow with our experience dedication and service A leader in generic drugs CBD is becoming more popular with consumers and is available in an growing array of products forms and doses The Hemp Business Journal an online publication that tracks the U S hemp industry estimates that the market for hemp derived CBD products will grow from 390 million in 2018 to 13 billion by 2022 Commercial activity has accelerated since Congress passed the 2018 Farm Bill in December which advocates said opens the door to increased cultivation production distribution and marketing of hemp derived products in the U S Hemp a variety of the Cannabis sativa plant has traditionally been used to make rope textiles and other products but most of the crop today is grown to satisfy demand for The broader health benefits remain unclear CBD a nonpsychoactive chemical present in modest amounts in marijuana and hemp plants Enthusiasts tout CBD as an aid in maintaining healthy lifestyles and as a treatment for a range of chronic illnesses and conditions The FDA recently approved a CBD concentrate Epidiolex to treat rare forms of epilepsy Yet the broader health benefits remain unclear Clinical trials in the U S are exploring whether the extract could help treat anxiety post traumatic stress disorder Parkinsons disease tremors and chronic pain But scientists and regulators generally agree that the research is limited and more needs to be done The FDA which considers CBD to be a drug ingredient currently prohibits restaurant and food manufacturers from adding CBD to food and drinks And the agency has sent warning letters to companies for making health claims without federal approval Still the agency recently acknowledged that the government Chain Drug Review April 29 2019 71